Biological Evaluation of Lysionotin: A Novel Inhibitor of 5-Lipoxygenase for Anti-glioma

被引:0
|
作者
SHAO Xinxin [1 ]
CHEN Cong [2 ,3 ]
LIU Jie [4 ]
LI Qingjun [5 ]
HE Shan [4 ]
QI Xianghua [1 ,6 ]
FU Xianjun [3 ,7 ]
WANG Zhenguo [2 ,3 ]
机构
[1] The First Clinical College of Medicine, Shandong University of Traditional Chinese Medicine
[2] Institute for Literature and Culture of Chinese Medicine, Shandong University of Traditional Chinese Medicine
[3] Key Laboratory of Classical Theory of Traditional Chinese Medicine, Ministry of Education, Shandong University of Traditional Chinese Medicine
[4] College of Pharmacy, Shandong University of Traditional Chinese Medicine
[5] Experimental Center, Shandong University of Traditional Chinese Medicine
[6] Neurology Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine
[7] Marine Traditional Chinese Medicine Research Center, Qingdao Academy of Traditional Chinese Medicine, Shandong University of Traditional Chinese
关键词
D O I
暂无
中图分类号
R739.4 [神经系肿瘤];
学科分类号
摘要
Objective: To explore the potential mechanism of lysionotin in treating glioma. Methods: First, target prediction based on Bernoulli Na?ve Bayes profiling and pathway enrichment was used to predict the biological activity of lysionotin. The binding between 5-lipoxygenase(5-LO) and lysionotin was detected by surface plasmon resonance(SPR) and molecular docking, and the inhibitory effects of lysionotin on 5-LO and proliferation of glioma were determined using enzyme inhibition assay in vitro and cell viability analysis, respectively. Furthermore, the pharmaceutical effect of lysionotin was explored by cell survival rate analysis and liquid chromatography with tandem mass spectrometry(LC-MS/MS). The protein expression, intracellular calcium ion concentration and cytoskeleton detection were revealed by Western blot, flow cytometry and fluorescence labeling, respectively. Results: Target prediction and pathway enrichment revealed that lysionotin inhibited 5-LO, a key enzyme involved in the arachidonic acid metabolism pathway, to inhibit the proliferation of glioma. Molecular docking results demonstrated that 5-LO can be binding to lysionotin through hydrogen bonds, forming bonds with His600, Gln557, Asn554, and His372. SPR analysis further confirmed the interaction between 5-LO and lysionotin. Furthermore, enzyme inhibition assay in vitro and cell survival rate analysis revealed that 50% inhibition concentration of lysionotin and the median effective concentration of lysionotin were 90 and 16.58 μmol/L, respectively, and the results of LC-MS/MS showed that lysionotin inhibited the production of 5S-hydroperoxy-eicosatetraenoic acid(P<0.05), and moreover, the LC-MS/MS results indicated that lysionotin can enter glioma cells well(P<0.01) and inhibit their proliferation. Western blot analysis demonstrated that lysionotin can inhibit the expression of 5-LO(P<0.05) and downstream leukotriene B4 receptor(P<0.01). In addition, the results showed that lysionotin affected intracellular calcium ion concentration by inhibiting 5-LO to affect the cytoskeleton, as determined by flow cytometry and fluorescence labeling. Conclusion: Lysionotin binds to 5-LO could suppress glioma by inhibiting arachiodonic acid metabolism pathway.
引用
收藏
页码:826 / 834
页数:9
相关论文
共 50 条
  • [31] Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies
    Marr, K
    Marsh, K
    Hernandez, L
    Cunningham, FM
    Lees, P
    RESEARCH IN VETERINARY SCIENCE, 1998, 64 (02) : 111 - 117
  • [32] Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase
    Filosa, Rosanna
    Peduto, Antonella
    Aparoy, Polamarasetty
    Schaible, Anja M.
    Luderer, Susann
    Krauth, Verena
    Petronzi, Carmen
    Massa, Antonio
    de Rosa, Mario
    Reddanna, Pallu
    Werz, Oliver
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 67 : 269 - 279
  • [33] ZILEUTON - A 5-LIPOXYGENASE INHIBITOR IN RHEUMATOID-ARTHRITIS
    WEINBLATT, ME
    KREMER, JM
    COBLYN, JS
    HELFGOTT, S
    MAIER, AL
    PETRILLO, G
    HENSON, B
    RUBIN, P
    SPERLING, R
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (10) : 1537 - 1541
  • [34] Synthesis and Structural Proof of a Potent 5-Lipoxygenase Inhibitor
    Balu, Devipriya
    Poomani, Kumaradhas
    Nagabushanam, Kalyanam
    Balasubramanium, Sridhar
    Ramanujam, Rajendran
    Muhammed, Majeed
    JOURNAL OF CHEMICAL CRYSTALLOGRAPHY, 2011, 41 (05) : 697 - 702
  • [35] Synthesis and Structural Proof of a Potent 5-Lipoxygenase Inhibitor
    Devipriya Balu
    Kumaradhas Poomani
    Kalyanam Nagabushanam
    Sridhar Balasubramanium
    Rajendran Ramanujam
    Majeed Muhammed
    Journal of Chemical Crystallography, 2011, 41 : 697 - 702
  • [36] TOPICAL TREATMENT OF PSORIASIS WITH A SELECTIVE 5-LIPOXYGENASE INHIBITOR
    JANSEN, CT
    LAMMINTAUSTA, K
    BULLINGHAM, RES
    FORSSTROM, S
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (02) : 154 - 154
  • [37] The Discovery of Setileuton, a Potent and Selective 5-Lipoxygenase Inhibitor
    Ducharme, Yves
    Blouin, Marc
    Brideau, Christine
    Chateauneuf, Anne
    Gareau, Yves
    Grimm, Erich L.
    Juteau, Helene
    Laliberte, Sebastien
    MacKay, Bruce
    Masse, Frederic
    Ouellet, Marc
    Salem, Myriam
    Styhler, Angela
    Friesen, Richard W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (04): : 170 - 174
  • [38] EFFECT OF 5-LIPOXYGENASE INHIBITOR ON CANINE PANCREATIC ALLOTRANSPLANTATION
    HORICHI, H
    IZUMI, R
    SHIMIZU, K
    KONISHI, K
    KITABAYASHI, K
    WATANABE, T
    MIYAZAKI, I
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (01) : 1679 - 1680
  • [39] Treatment of inflammatory acne with an oral 5-lipoxygenase inhibitor
    Zouboulis, C
    Nestoris, S
    Adler, Y
    Picardo, M
    Camera, E
    Orth, M
    Orfanos, C
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 547 - 547
  • [40] Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma
    Wenzel, SE
    Kamada, AK
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) : 858 - 864